Elgan Pharma is developing ELGN-EYE, a non-invasive therapy that stimulates normal retinal development in preterm infants to prevent vision impairment caused by retinopathy of prematurity. This technology addresses the critical need for effective interventions in a population at high risk for visual complications due to premature birth.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Premature infants are at high risk for developing retinopathy of prematurity (ROP), a major cause of vision impairment or blindness due to abnormal retinal development. Currently, there are limited effective and non-invasive therapies available to stimulate normal retinal development and prevent ROP in this vulnerable population.
Solution
Elgan Pharma is developing ELGN-EYE, a non-invasive therapeutic approach designed to promote normal retinal development in preterm infants, thereby preventing vision impairment caused by ROP. ELGN-EYE aims to address the underlying causes of ROP by stimulating the retina and reducing inflammation and oxidative stress. This therapy offers a proactive strategy to improve visual outcomes and overall quality of life for newborns at risk of ROP, addressing a critical unmet medical need with a safe and non-invasive solution.
Target Audience
The primary target audience includes preterm infants at risk of developing retinopathy of prematurity (ROP) and the neonatologists and other medical professionals who provide care for these infants.
Features
- Non-invasive therapy administered to preterm infants
- Designed to stimulate normal retinal development
- Reduces inflammation and oxidative stress in the retina
- Targets the prevention of vision impairment due to retinopathy of prematurity (ROP)